4 results about "Membrane bound" patented technology

This invention relates to a method for detecting and predicting chilling injury in peach fruit, comprising the following steps: cutting the fruit pulp into sections and randomly grouping them; subjecting each group of pulp to high-pressure treatment at different pressures; adding a dissociation solution to the pulp in different groups to dissociate membrane-bound polyphenol oxidases in the pulp; and measuring the enzyme activities (B1, B2, B3, B4…B) of the membrane-bound polyphenol oxidases in the pulp treated at different pressures. n The dissociated membrane-bound polyphenol oxidase was activated by adding an activator, and then the enzyme activity C was measured. The activation rates under different high-pressure treatment conditions were B1 / C, B2 / C, B3 / C, B4 / C…B. n / C; Based on the activation rate under high-pressure treatment at different pressures, the pressure value P corresponding to the activation rate discrimination standard value R is calculated. Then, based on the prediction equation between the pressure value P and the storable time, the storable time is calculated. This method can quickly and early detect chilling injury and can also predict the storable time of unknown peach fruits.

Systems, methods and compositions for the production and use of Saccharomyces-generated extracellular vesicles having a membrane-bound nucleic acid transport system adapted to actively transport one or more nucleic acids into the lumen of the vesicle.

This invention presents the CVOM-2 Gram-negative bacterial strain of Caulobacter crescentus, which has a point mutation in the ompA2 gene resulting in the substitution of arginine 351 for alanine, and a null mutation in the rsaA gene that produces outer membrane vesicles (EMVs) with greater efficiency, quantified as the amount of protein / ml of original culture. These EMVs produce a lower inflammatory response than similar preparations obtained from wild-type Escherichia coli cells or cells modified to reduce this response, or even than preparations obtained from a Caulobacter crescentus strain with a wild-type cell envelope.Genetic methods are also presented that allow the modification of these membrane-bound extracellular matrices (MBs), resulting in the presence of a heterologous protein or antigen in soluble form within the vesicle lumen or associated with the vesicle membrane as part of an integral membrane protein. The antigen may be exposed to the lumen or the vesicle surface, or anchored to the outer membrane via lipids. These MBs induce the generation of antibodies against a heterologous protein present within them. MBs also have an adjuvant effect, inducing antibody generation in response to antigen concentrations that would not otherwise elicit this response.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a siRNA targeting ADAM17 gene based on intestinal barrier repair and application thereof in improving visceral hypersensitivity of IBS. The siRNA silences ADAM17 expression, inhibits abnormal cleavage of IL-10 receptor alpha subunit (IL-10RA) on the membrane of intestinal epithelial cells, maintains the integrity of the membrane-bound IL-10 receptor, restores IL-10 protective signaling, up-regulates tight junction proteins such as ZO-1 and Occludin, reduces intestinal permeability, repairs intestinal mucosal barrier, and finally improves colorectal distension-induced pain threshold and relieves visceral hypersensitivity. Animal model experiments show that the siRNA can significantly reduce the expression of ADAM17 protein in the colon, improve the structure and function of the barrier, and increase the pain threshold, and has application prospects as a new molecular targeted treatment for IBS.